Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32006
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlberto, Matthew-
dc.contributor.authorYim, Arthur-
dc.contributor.authorLawrentschuk, Nathan-
dc.contributor.authorBolton, Damien M-
dc.date2023-
dc.date.accessioned2023-01-24T03:20:01Z-
dc.date.available2023-01-24T03:20:01Z-
dc.date.issued2023-01-04-
dc.identifier.citationCancers 2023; 15(2)en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/32006-
dc.description.abstractProstate cancer is the second most frequent cancer in men, with increasing prevalence due to an ageing population. Advanced prostate cancer is diagnosed in up to 20% of patients, and, therefore, it is important to understand evolving mechanisms of progression. Significant morbidity and mortality can occur in advanced prostate cancer where treatment options are intrinsically related to lipid metabolism. Dysfunctional lipid metabolism has long been known to have a relationship to prostate cancer development; however, only recently have studies attempted to elucidate the exact mechanism relating genetic abnormalities and lipid metabolic pathways. Contemporary research has established the pathways leading to prostate cancer development, including dysregulated lipid metabolism-associated de novo lipogenesis through steroid hormone biogenesis and β-oxidation of fatty acids. These pathways, in relation to treatment, have formed potential novel targets for management of advanced prostate cancer via androgen deprivation. We review basic lipid metabolism pathways and their relation to hypogonadism, and further explore prostate cancer development with a cellular emphasis.en_US
dc.language.isoeng-
dc.subjectandrogen deprivationen_US
dc.subjectgeneticsen_US
dc.subjectlipid metabolismen_US
dc.subjectprostate canceren_US
dc.titleDysfunctional Lipid Metabolism-The Basis for How Genetic Abnormalities Express the Phenotype of Aggressive Prostate Cancer.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleCancersen_US
dc.identifier.affiliationUrologyen_US
dc.identifier.affiliationDepartment of Urology, Royal Melbourne Hospital, Melbourne, VIC 3010, Australia.en_US
dc.identifier.affiliationDepartment of Urology, Austin Health, University of Melbourne, Melbourne, VIC 3010, Australia.en_US
dc.identifier.doi10.3390/cancers15020341en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-3722-7754en_US
dc.identifier.orcid0000-0003-2045-1231en_US
dc.identifier.orcid0000-0001-8553-5618en_US
dc.identifier.orcid0000-0002-5145-6783en_US
dc.identifier.pubmedid36672291-
dc.description.volume15-
dc.description.issue2-
local.name.researcherBolton, Damien M
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
crisitem.author.deptUrology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

52
checked on Nov 4, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.